Study discontinuation in clinical research does not refer to a single process; it may mean the end of an individual participant’s involvement, discontinuation of the study treatment with continued follow-up, or the premature termination of the entire clinical trial. These levels have different causes, consequences and documentation requirements. A precise distinction is necessary for participant rights, safety, data quality and regulatory reporting.
Withdrawal by a participant
A participant may withdraw their consent at any time without having to fear any disadvantages. The withdrawal may concern the participant’s entire further involvement in the study or individual components, such as additional samples or further contact. The trial site clarifies the scope of the withdrawal, respects the decision and documents it in a comprehensible manner. Data already lawfully collected and activities already carried out are not retroactively rendered invalid by the withdrawal in accordance with the Regulation.
Individual discontinuation is not a quality deficiency on the part of the participant. Reasons may include burden, adverse effects, relocation, lack of benefit or personal preference. If the participant permits this and the protocol provides for it, safety-related follow-up may be discussed. However, it must not continue against the participant’s clearly expressed wishes. Even in the event of discontinuation, safety and appropriate medical care must be taken into account.
Discontinuation of treatment with continued follow-up
Termination of the study treatment must be distinguished from complete withdrawal. A participant may discontinue the investigational intervention, or the investigator may discontinue it for safety reasons, in the event of a contraindication, pregnancy or a deviation. In this case, the person remains in the trial, provided they consent and the protocol provides for this, and participates in safety or endpoint visits. Treatment ends; data collection does not automatically end.
This distinction is methodologically important. Endpoints, adverse events and the reasons for discontinuation may remain relevant for the benefit-risk assessment. The protocol should therefore specify criteria for interrupting or terminating the intervention, further care and the type of follow-up. The trial site documents the reason, time, scope and follow-up measures so that treatment exposure and observation time can be correctly evaluated.
Premature termination of the entire study
Premature termination of the entire clinical trial occurs when the sponsor terminates the study before its planned end at all participating trial sites. The closure of an individual trial site must be distinguished from this and assessed as to whether it has implications for participants, safety or the continuation of the study. Triggers may include, for example, an unfavourable benefit-risk ratio, new safety data, lack of feasibility or a justified scientific decision. The decision must not neglect the protection of persons already enrolled: Further treatment, information, safety follow-up and the processing of data already generated must be planned in advance.
Regulation (EU) No 536/2014 governs notification of premature termination and the provision of reasons and follow-up measures. The sponsor, trial sites and, where applicable, the investigator must coordinate their responsibilities. The clinical trial report and study documentation must show whether the trial ended as planned, was temporarily halted or was prematurely terminated. Premature termination of the entire study is therefore not merely the sum of individual discontinuations.
Relevance for clinical trials
Discontinuation processes must be clearly defined in the protocol, informed consent documents and work instructions before the start of the study. Essential elements include clear discussion procedures, medical follow-up measures, coding of reasons and escalation pathways for safety decisions. Monitoring should in particular verify whether treatment and follow-up are documented separately and whether a withdrawal of consent has been correctly implemented.
Full-service CROs such as Mediconomics support the planning of discontinuation and follow-up processes, the drafting of protocol texts and informed consent documents, safety management, monitoring and the coordination of regulatory notifications. Clinical Operations, data management, biostatistics and pharmacovigilance can thereby consistently record the reasons, timing and consequences of discontinuations and make them usable for analysis and safety assessment.
Frequently Asked Questions (FAQ)
Is a drop-out the same as study discontinuation?
Drop-out is often used imprecisely to describe participation that was not completed in full. For operational and regulatory documentation, however, it must be clarified whether this refers to a withdrawal, discontinuation of treatment with follow-up or premature termination of the entire study.
Is lost to follow-up a withdrawal?
No. Lost to follow-up describes a situation in which planned follow-up is no longer possible despite reasonable attempts to make contact. A withdrawal, by contrast, is an expressed decision by the participant concerning further participation or data use.
Can data already collected be used after a withdrawal?
Under the Regulation, a withdrawal does not affect activities that have already been carried out or data collected before the withdrawal. The specific approach is additionally governed by the protocol and applicable data protection law.
Regulatory references
- Regulation (EU) No 536/2014, Articles 28 and 37 – protects the withdrawal of consent and regulates notifications in the event of a temporary halt or premature termination.
- ICH E6(R3) Good Clinical Practice – requires an approach to discontinuation, safety and data quality to be described in the protocol.
- ICH E8(R1) General Considerations for Clinical Studies – assigns the planning of relevant data and follow-up to the objectives of the study.
- EudraLex Volume 10 – contains EU guidelines and questions and answers on the practical application of Regulation (EU) No 536/2014.